Therapeutic Targeting and Monitoring Tumor Microenvironments
Terrace Ballroom IV (400 Level), Pennsylvania Convention Center
Methods Workshop
Systems Approaches to Cancer
Room 121, Pennsylvania Convention Center
Educational Session
From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 1:
Optimizing Drug Discovery: Insights on an Important Process
Room 113, Pennsylvania Convention Center
Tumor Immunology and Immunotherapy for the Non-Immunologist
Grand Ballroom (300 Level), Pennsylvania Convention Center
Saturday, 10:15 AM - 12:15 PM
Educational Session
Bench to Bedside and Back Again: Biology and Therapy of ALK and BRAF Cancers
Room 115, Pennsylvania Convention Center
Computational and Functional Modeling of Hot Big Data
Room 204, Pennsylvania Convention Center
Methods Workshop
How and When to Use Chemical Probes
Room 118, Pennsylvania Convention Center
Educational Session
Pediatric Low Grade Gliomas: Silent But Still Deadly
Room 114, Pennsylvania Convention Center
Methods Workshop
Large Scale Functional Genomic Screens: In Need of Controls?
Grand Ballroom (300 Level), Pennsylvania Convention Center
Saturday, 1:00 PM - 3:00 PM
Educational Session
Mechanisms of Cancer Therapy Resistance
Room 204, Pennsylvania Convention Center
Role of Non-Coding RNAs in Cancer
Terrace Ballroom IV (400 Level), Pennsylvania Convention Center
Chemical Biology and Molecular Pharmacology
Room 103, Pennsylvania Convention Center
Tumor Heterogeneity and Evolution
Terrace Ballroom II-III (400 Level), Pennsylvania Convention Center
Methods Workshop
Cell Line Authentication: Improving the Reproducibility and Translatability of
Preclinical Cancer Research
Room 108, Pennsylvania Convention Center
Design and Method Workshop for Clinical Trials and Population Studies, Part 3:
Challenges of Genomics, Integromics, and Tumor Heterogeneity in Clinical Trial
Designs
Room 201, Pennsylvania Convention Center
Saturday, 3:15 PM - 5:15 PM
Educational Session
Translating Insights from Mouse Cancer Models to Therapeutic Targeting
Room 114, Pennsylvania Convention Center
Endogenous Steroid Hormones and Risk of Cancer
Room 120, Pennsylvania Convention Center
Therapeutic Targeting the Diverse Immune Inhibitory Pathways in the Tumor
Microenvironment
Terrace Ballroom II-III (400 Level), Pennsylvania Convention Center
Apr 19
Sunday, 7:00 AM - 8:00 AM
Meet-the-Expert Session
Unraveling Hormone Dependence in Cancer
Room 119, Pennsylvania Convention Center
Novel Therapeutic Targets in Myeloma
Room 113, Pennsylvania Convention Center
The Biologic Signature of Melanoma to Guide Therapy
Room 120, Pennsylvania Convention Center
The Promise of Personalized Medicine
Room 201, Pennsylvania Convention Center
Sunday, 9:30 AM - 12:00 PM
Plenary Session
Opening Plenary: The Genome and Beyond
Hall A (200 Level), Pennsylvania Convention Center
Sunday, 1:00 PM - 5:00 PM
Poster Session
Therapeutic Resistance in Lung Cancer
Section 31
Therapeutic Resistance in Hormone-Sensitive Cancers
Tyrosine Kinase and Phosphatase
Inhibitors
Section 32
Signal Transduction Inhibitors
Section 28
Kinases and Inhibitors
Section 6
Cell Adhesion and Extracellular Matrix
Section 15
Tumor- and Blood-based Genotyping
Section 26
Targeting Signal Transduction
Section 29
Predictive Biomarkers: Lung and Gastrointestinal Cancers
Section 24
Crosstalk of the Microenvironment and the Tumor Clone
Section 17
Cell Signaling in Cancer 1
Section 2
Histone Methylation and Acetylation
Section 5
Long Non-Coding RNAs
Section 7
Cell Death Mechanisms
Section 1
3D Cultures and Tissue/Organoid Models
Section 14
Immune Checkpoints
Section 12
MicroRNA Regulation of Cancer Biology
Section 8
Carcinogenic Mechanisms 1
Section 34
Signaling Axes Regulating Motility and Invasion
Section 21
New Insights from Imaging and Cell Isolation
Section 9
Modeling Cancer Prevention
Section 37
Late-Breaking Poster Session
Late-Breaking Research: Experimental and Molecular Therapeutics 1
Section 39
Late-Breaking Research: Molecular and Cellular Biology 1
Section 41
Poster Session
Pediatric Cancer: Basic Science 1
Section 20
Circulating Tumor Cells and Disseminated Tumor Cells
Section 16
Deregulation of Gene Expression in Prostate Cancer and Sarcoma
Section 4
Sunday, 1:00 PM - 3:00 PM
Drug Development Track: Special Session
New Drugs on the Horizon 1
Room 204, Pennsylvania Convention Center
Sunday, 1:00 PM - 5:00 PM
Poster Session
Computational Tools / Genomic Profiling of Tumors
Section 3
Prognostic and Toxicity Biomarkers
Section 25
Diagnostic Biomarkers
Section 23
Sunday, 1:00 PM - 3:00 PM
Major Symposium
Autophagy and Cancer
Room 115, Pennsylvania Convention Center
Sunday, 1:00 PM - 5:00 PM
Poster Session
Non-Coding RNAs in Cancer Biology 1
Section 10
Cytokines and Chemokines and the Microenvironment
Section 18
Tumor Microenvironment/Innate Immune Activators
Section 13
Sunday, 3:00 PM - 5:00 PM
Regulatory Science and Policy Session
Evolution of Personalized Drug Development in Oncology-Kinase Inhibitors
Room 119, Pennsylvania Convention Center
Sunday, 3:15 PM - 5:15 PM
Late-Breaking Minisymposium
Minisymposium: Late-Breaking Research
Room 122, Pennsylvania Convention Center
Minisymposium
Signaling of the Microenvironment Regulates Tumor Progression
Room 113, Pennsylvania Convention Center
Oncogenic Signaling and Cell Death
Room 121, Pennsylvania Convention Center
Liquid Biopsies
Terrace Ballroom I (400 Level), Pennsylvania Convention Center
Biomarkers and Cancer: New Insights
Terrace Ballroom IV (400 Level), Pennsylvania Convention Center
Cell Cycle Mechanisms of Anticancer Drug Action
Room 120, Pennsylvania Convention Center
Drug Discovery: New Targets and Antibody Drug Conjugates
Room 201, Pennsylvania Convention Center
Cancer Stem Cells 1
Room 115, Pennsylvania Convention Center
Clinical Trials Minisymposium
Clinical Trials Minisymposium
Room 103, Pennsylvania Convention Center
Sunday, 3:15 PM - 5:30 PM
Minisymposium
Cancer Genomics: Characterization, Evolution, and Function
Room 114, Pennsylvania Convention Center
Sunday, 3:15 PM - 5:15 PM
Drug Development Track: Special Session
New Drugs on the Horizon 2
Room 204, Pennsylvania Convention Center
Sunday, 5:30 PM - 6:30 PM
Awards and Lectures
Presidential Address
Hall A (200 Level), Pennsylvania Convention Center
Apr 20
Monday, 7:00 AM - 8:00 AM
Meet-the-Expert Session
Molecular Pathology in Oncology
Room 114, Pennsylvania Convention Center
Examination of Cancer Pathways Using Computational Approaches
Section 4
Monday, 8:00 AM - 12:00 PM
Poster Session
Angiogenesis Inhibitors
Section 14
Pediatric Cancer: Clinical Investigations / Regulatory Science and Policy
Section 24
Cell Death and Survival
Section 1
In Vitro and In Vivo Models and New Targets
Section 30
Inhibitors of UPS and HSP90 Pathways and Other Targets
Section 31
Cell Cycle, DNA, and Transcription Targets
Section 28
Human-in-Mouse Models of Cancer 1
Section 17
Epithelial-Mesenchymal Transition, Mesenchymal-Epithelial Transition, and Related
Behaviors
Section 16
Unfolded Protein Response and Oxidative Stress
Section 10
Novel Agents and Mechanisms of Action
Section 32
Molecular Endocrinology of Cancer 1
Section 36
Cell Signaling in Cancer 2
Section 2
Metabolic Pathways and Signaling Pathways That Regulate Metabolism
Monday, 1:00 PM - 5:00 PM
Poster Session
Resistance to Pathway-Targeted Therapeutics 1
Section 33
Session Title:
Cell Signaling in Cancer 3
Session Type:
Poster Session
Session Start/End Time: Monday, Apr 20, 2015, 1:00 PM - 5:00 PM
Location:
Section 3
CME:
(not eligible for CME credit)
Session Category:
Molecular and Cellular Biology
1967: Elucidation of signaling pathways that mediate gastrin-induced
vation and pGSK3β/Snail induction in gastric cancer cells
Apr 20, 2015, 1:00 PM - 5:00 PM
Basu1, Goutam Sondarva2, Sreevidya Santha1, Ajay Rana2, Basabi Rana1. 1Department of
, Division of Gastroenterology & Nutrition, Loyola University Chicago, Maywood, IL;
ment of Pharmacology and Experimental Therapeutics, Loyola University Chicago,
d, IL
1968: Activation of AKT negatively regulates the pro-apoptotic function
of death-associated protein kinase 3 (DAPK3) in prostate cancer
Monday, Apr 20, 2015, 1:00 PM - 5:00 PM
Trinath P. Das1, Arokya MS Papu John1, Ram V. Roy2, Sandhya R.
Rao3, Houda Alatassi3, Chendil Damodaran1, Murali M. Ankhem4.
1
Clinical and tranlational research, University of Louisville, Louisville,
KY; 2University of Kentucky, Lexington, KY; 3University of Louisville,
Louisville, KY; 4University of Louisville School of Medicine, Louisville,
KY
1969: Regulation of cell cycle progression in BRAFV600E
inhibitor-resistant human melanoma by histone deacetylase inhibitor
Monday, Apr 20, 2015, 1:00 PM - 5:00 PM
Antoni X. Toresss-Collado, Ramin Nazarian, Ali R. Jazirehi. UCLA
David Geffen School of Medicine, Los Angeles, CA
1940: Dual inhibition of mTORC1/C2 and HER2 results in maximal antitumor efficacy in preclinical model
of HER2+ breast cancer resistant to trastuzumab therapy
Monday, Apr 20, 2015, 1:00 PM - 5:00 PM
Pradip Kr De, Yuliang Sun, Jennifer H. Carlson, Xiaoqian Lin, Nandini Dey, Brian Leyland-Jones. Avera
Research Institute, Sioux Falls, SD
Session Title:
Targeting Pathway Rewiring to Improve Cancer Therapy
Session Type:
Major Symposium
Session Start/End Time: Monday, Apr 20, 2015, 1:00 PM - 3:00 PM
Location:
Room 103, Pennsylvania Convention Center
CME:
CME-Designated
CME/CE Hours:
2
Session Description:
Both the emergence of malignant cells, and their subsequent resistance
to killing by molecularly targeted and cytotoxic therapies arises from
re-wiring of signaling pathways that control cell growth, proliferation,
invasion, and programmed cell death. This session will review how the
continual ability of cancer cells to re-wire signaling pathways leads to
the emergence of therapeutic resistance, both through tumor cell
autonomous changes and through tumor cell manipulation of the local
microenvironment. Presenters will then demonstrate how a detailed
molecular understanding of this process can lead to novel therapeutic
strategies that can kill these resistant clones and/or prevent their
emergence. Finally, this session will show how the inherent plasticity
of signaling pathways in cancer can also be taken advantage of
therapeutically in order to make tumor cells sensitive to drugs that they
were not previously sensitive to, through a process called “therapeutic
dynamic re-wiring”
Presentations:
Chairperson
Monday, Apr 20, 2015, 1:00 PM - 3:00 PM
Michael B. Yaffe. MIT Koch Institute for Integrated Cancer Research, Cambridge, MA
Introduction
Monday, Apr 20, 2015, 1:00 PM - 1:10 PM
SY19-01: Therapeutic network re-wiring of the DNA damage response can be used to
enhance tumor killing by cytotoxic chemotherapy
Monday, Apr 20, 2015, 1:10 PM - 1:30 PM
Michael J. Lee, Yogesh Dayma, Anne-Margriet Heijinks, Stephen W. Morton, Erik C.
Dreaden, Paula T. Hammond, Michael B. Yaffe. MIT Koch Institute for Integrated Cancer
Research, Cambridge, MA, MIT Koch Institute for Integrated Cancer Research,
Cambridge, MA
Discussion
Monday, Apr 20, 2015, 1:30 PM - 1:35 PM
Cancer cell-state plasticity and resistance to therapy
Monday, Apr 20, 2015, 1:35 PM - 1:55 PM
Rafaella Sordella. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
Discussion
Monday, Apr 20, 2015, 1:55 PM - 2:00 PM
SY19-03: Rewiring of signaling associated protein complexes in cancer
Monday, Apr 20, 2015, 2:00 PM - 2:20 PM
Eric B. Haura. Moffitt Cancer Center & Research Institute, Tampa, FL
Discussion
Monday, Apr 20, 2015, 2:20 PM - 2:25 PM
Resiliency of the kinome to targeted kinase inhibitors: Strategies to block rewiring
Monday, Apr 20, 2015, 2:25 PM - 2:45 PM
Gary L. Johnson. University of North Carolina at Chapel Hill School of Medicine, Chapel
Hill, NC
Session Title:
Molecular Mechanisms of Sensitivity or Resistance to PathwayTargeted Agents
Session Type:
Minisymposium
Session Start/End Time: Monday, Apr 20, 2015, 3:00 PM - 5:00 PM
Location:
Room 118, Pennsylvania Convention Center
CME:
CME-Designated
CME/CE Hours:
2
Session Category:
Experimental and Molecular Therapeutics
Presentations:
Chairperson
Monday, Apr 20, 2015, 3:00 PM - 5:00 PM
Paul Workman. The Institute of Cancer Research, London, United Kingdom
Chairperson
Monday, Apr 20, 2015, 3:00 PM - 3:05 PM
Richard M. Marais. Cancer Research UK Manchester Institute, Manchester, United
Kingdom
Introduction
Monday, Apr 20, 2015, 3:00 PM - 3:05 PM
2841: A co-clinical assessment of patterns of BRAF inhibitor resistance
Monday, Apr 20, 2015, 3:05 PM - 3:20 PM
Lawrence N. Kwong1, Genevieve Boland1, Dennie Frederick2, Timothy Helms1, Ahmad
Akid1, John Miller1, Shan Jiang1, Zachary Cooper1, Xingzhi Song1, Sahil Seth1, Jennifer
Kamara1, Alexei Protopopov1, Gordon Mills1, Keith Flaherty2, Jennifer Wargo1, Lynda
Chin1. 1UT MD Anderson Cancer Center, Houston, TX; 2Massachusetts General Hospital,
Boston, MA
2842: Personalized pre-clinical trials in BRAF inhibitor resistant patient derived xenograft
models of melanoma identify c-Met as an effective second line combination therapy target
Monday, Apr 20, 2015, 3:20 PM - 3:35 PM
Clemens Krepler1, Min Xiao1, Katrin Sproesser1, Patricia Brafford1, Batool Shannan1,
Marilda Beqiri1, Wei Xu2, Bradley Garman2, Katherine L. Nathanson2, Xiaowei Xu2,
Giorgos Karakousis2, Gordon B. Mills3, Yiling Lu3, Giordano Caponigro4, Markus
Boehm4, Malte Peters4, Lynn Schuchter2, Meenhard Herlyn1. 1The Wistar Institute,
Philadelphia, PA; 2University of Pennsylvania Abramson Cancer Center, Philadelphia, PA;
3
University of Texas MD Anderson Cancer Center, Huston, TX; 4Novartis Oncology
Translational Medicine, Cambridge, MA
2843: Resistance to ERK inhibitors as a result of an acquired novel P-loop mutation of
ERK2
Monday, Apr 20, 2015, 3:35 PM - 3:50 PM
Paul A. Clarke, Toby Roe, Kate Swabey, Craig McAndrew, Kathy Boxall, Isaac
Westwood, Robert van Montfort, Bissan Al-Lazikhani, Paul Workman. Cancer Research
UK Cancer Therapeutics Unit, Institute of Cancer Research, London, United Kingdom
2844: RNA interference kinome-wide screen reveals a role for PDK1 in acquired resistance
to CDK4/6 inhibition ER-positive breast cancer
Monday, Apr 20, 2015, 3:50 PM - 4:05 PM
Valerie M. Jansen, Neil E. Bhola, Joshua A. Bauer, Carlos L. Arteaga. Vanderbilt,
Nashville, TN
2845: Co-acquisition of T790M and EMT in resistant EGFR mutant non-small cell lung
cancer can be overcome by combined irreversible EGFR and BCL-XL inhibition
Monday, Apr 20, 2015, 4:05 PM - 4:20 PM
Aaron N. Hata1, Matthew J. Niederst1, Hannah L. Archibald1, Hillary Mulvey1, Jungoh
Ham2, Maria Gomez-Caraballo1, Anuj Kalsy1, Anthony C. Faber2, Jeffrey Engelman1.
1
Massachusetts General Hospital, Boston, MA; 2Virginia Commonwealth University,
Richmond, VA
2846: Ultrasensitive detection of actionable subclones in chronic myeloid leukemia
Monday, Apr 20, 2015, 4:20 PM - 4:35 PM
Michael W. Schmitt, Bella Aminov, Jerald P. Radich, Lawrence A. Loeb. University of
Washington, Seattle, WA
2847: High complexity barcoding to study clonal dynamics in response to cancer therapy
Monday, Apr 20, 2015, 4:35 PM - 4:50 PM
Hyo-eun C. Bhang1, David A. Ruddy1, Viveksagar Krishnamurthy Radhakrishna1, Rui
Zhao2, Iris Kao1, Daniel Rakiec1, Pamela Shaw1, Marissa Balak1, Justina X. Caushi1,
Elizabeth Ackley1, Nicholas Keen1, Michael R. Schlabach1, Michael Palmer1, William R.
Sellers1, Franziska Michor2, Vesselina G. Cooke1, Joshua M. Korn1, Frank Stegmeier1.
1
Novartis Institutes for BioMedical Research, Cambridge, MA; 2Dana-Farber Cancer
Institute, Boston, MA
Session Title:
Resistance to Pathway-Targeted Therapeutics 2
Session Type:
Poster Session
Session Start/End Time: Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Location:
Section 31
CME:
(not eligible for CME credit)
Session Category:
Experimental and Molecular Therapeutics
Presentations:
3578: Dual mTOR kinase inhibitor overcomes rapamycin resistance in vitro
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Yao Dai1, Li Zhao2, Dietmar Siemann1. 1University of Florida, Gainesville, FL; 2China
Pharmaceutical University, Nanjing, China
3579: Identification of biomarkers of AXL-mediated drug resistance in head and neck
squamous cell carcinoma
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Kavitha Balaji1, Robert Cardnell2, Lixia Diao3, Pan Tong3, Milena Mak2, You Hong Fan2,
Fatemeh Masrorpour2, Steven L. Warner4, David J. Bearss4, Ignacio Wistuba5, Gordon B.
Mills6, John Heymach2, Khandan Keyomarsi1, Jing Wang3, Lauren Averett Byers2.
1
Department of Experimental Radiation Oncology, MD Anderson Cancer Center, Houston,
TX; 2Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer
Center, Houston, TX; 3Department of Bioinformatics and Computational Biology, MD
Anderson Cancer Center, Houston, TX; 4Tolero Pharmaceutical, Inc., Lehi, UT;
5
Department of Translational Molecular Pathology, MD Anderson Cancer Center,
Houston, TX; 6Department of Systems Biology, MD Anderson Cancer Center, Houston,
TX
3580: Downregulated miR-30a promotes acquisition of chemoresistance by targeting
endothelin A receptor in ovarian carcinoma
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Rosanna Sestito1, Roberta Cianfrocca1, Laura Rosanò1, Elisa Semprucci1, Piera Tocci1,
Valeriana Di Castro1, Gabriella Ferrandina2, Anna Bagnato1. 1Regina Elena National
Cancer Inst., Rome, Italy; 2Gynecologic Oncology Unit, Catholic University of Rome,
Rome, Italy
3581: Rapid conversion to resistance, of a colon PDX with ret-fusion, by ponatinib
treatment could potentially be attributed to the introduction of the gate keeper mutation
V804M
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Mengmeng Yang, Jie Cai, Sheng Guo, Jean-Pierre Wery, Henry Qixiang Li. Crown
Bioscience, Inc., Santa Clara, CA
3582: Epidermal growth factor receptor and anaplastic lymphoma kinase bypass signaling
in oral squamous cell carcinoma in vivo
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Cara B. Gonzales1, Heping Chen1, Jorge J. De La Chapa1, Nameer B. Kirma2. 1UTHSCSA
Dental School, San Antonio, TX; 2UTHSCSA Medical School, San Antonio, TX
3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation
tyrosine kinase inhibitors
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Luca Mologni, Monica Ceccon, Diletta Fontana, Alessandra Pirola, Rocco Piazza, Carlo
Gambacorti-Passerini. University of Milano-Bicocca, Monza, Italy
3584: Lysine specific demethylase 1 inhibition attenuates enzalutamide resistant androgen
receptor V7 splice variant activation
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Sergio Regufe da Mota, Sarah Bailey, Rosemary A. Strivens, Annette L. Hayden, Graham
Packham, Simon J. Crabb. University of Southampton, Southampton, United Kingdom
3585: HER3 and IGF1R are major mediators of both acquired and intrinsic cetuximab
resistance in head and neck squamous cell carcinomas
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Ida Kjaer1, Trine Lindsted1, Camilla Fröhlich1, Ivan D. Horak1, Michael Kragh1, Jesper V.
Olsen2, Mikkel W. Pedersen1. 1Symphogen A/S, Ballerup, Denmark; 2The Novo Nordisk
Foundation Center for Protein Reasearch Faculty of Health and Medical Sciences
University of Copenhagen, Copenhagen, Denmark
3586: The use of kinome profiling to determine potential resistance pathways in pancreatic
cancer cells treated with PIM kinase inhibitors
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Vandana Singh1, Brittany Nixon1, T.S. Karim Gilbert2, Steve Warner3, David Bearss3, Lee
M. Graves2, Antonio T. Baines1. 1North Carolina Central University, Durham, NC;
2
University of North Carolina-Chapel Hill, Chapel Hill, NC; 3Tolero Pharmaceuticals, Salt
Lake City, UT
3587: Developing targeted therapy for the treatment of drug-resistant ovarian cancer
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Kelly M. Kreitzburg1, Zacchary Dobbins1, Ashwini Katre1, Tooba Anwer1, Ronald
Alvarez1, Charles N. Landen2, Karina J. Yoon1. 1University of Alabama at Birmingham,
Birmingham, AL; 2University of Virginia, Charlottesville, VA
3588: Emergence of multiple EGFR extracellular mutations during cetuximab treatment in
colorectal cancer
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Luca Lazzari1, Sabrina Arena1, Beatriz Bellosillo2, Giulia Siravegna1, Alejandro Martínez2,
Israel Cañadas2, Noelia Ferruz3, Mariangela Russo1, Sandra Misale1, Iria González2, Mar
Iglesias2, Elena Gavilan2, Giorgio Corti1, Sebastijan Hobor1, Giovanni Crisafulli1, Marta
Salido2, Juan Sánchez2, Alba Dalmases2, Joaquim Bellmunt2, Gianni De Fabritiis3, Ana
Rovira2, Federica Di Nicolantonio1, Joan Albanell2, Alberto Bardelli1, Clara Montagut2.
1
Candiolo Cancer Center, FPO-IRCCS, Candiolo (Torino), Italy; 2Hospital del Mar,
Barcelona, Spain; 3Computational Biophysics Laboratory (GRIB-IMIM), Pompeu Fabra
University, PRBB, Barcelona, Spain
3589: Validation of the role of circulating tumor DNA (ctDNA) in tracking mechanisms of
resistance to anti-EGFR monoclonal antibodies (AE-mABs): preliminary results of the
PROSPECT-C prospective trial
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Khurum Khan1, George Vlachogianis2, David Cunningham1, Jens Hahne2, Mahnaz
Darvish-Damavandi2, Sarah Barton2, Francesco Trevisani2, Giulia Mentrast2, Clare
Peckitt2, Andrea Lampis2, Chiara Braconi2, Nasir Khan2, Ruwaida Begum1, Naureen
Starling1, Sheela Rao3, David Watkins1, Annette Bryant1, Ian Chau1, Nicola Valeri2. 1The
Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom; 2The Institute of
Cancer Research, Sutton, Surrey, United Kingdom; 3the Royal Marsden NHS Foundation
Trust, Sutton, Surrey, United Kingdom
3590: Resistance mechanisms to ALK inhibitors
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Ryohei Katayama1, Noriko Yanagitani1, Sumie Koike1, Takuya Sakashita1, Satoru
Kitazono1, Makoto Nishio1, Yasushi Okuno2, Jeffrey A. Engelman3, Alice T. Shaw3,
Naoya Fujita1. 1Japanese Foundation for Cancer Research, Tokyo, Japan; 2Graduate School
of Medicine, Kyoto University, Kyoto, Japan; 3Massachusetts General Hospital Cancer
Center, Boston, MA
3591: Inhibition of heme oxygenase 1 decreases proliferation and resensitizes TKI-resistant
Flt3-ITD-positive AML cells
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Mary E. Irwin, Joya Chandra. UT MD Anderson Cancer Center, Houston, TX
3592: Androgens interfere with enzalutamide agonism of mutant F876L androgen receptor
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Daniel Coleman1, Katy Van Hook1, Robert Lisac1, Carly King1, Nicholas Wang1, Jacob
Schwartzman1, Martin Gleave2, Lina Gao1, Joshua Urrutia1, Laura Heiser1, Joshi J.
Alumkal1. 1Oregon Health & Science University, Portland, OR; 2University of British
Columbia, Vancouver, BC, Canada
3593: Raptor upregulation contributes to maintenance of 4EBP1 phosphorylation and
TORC kinase resistance in renal cancer cells
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Philip Earwaker, Frances Willenbrock, Andrew Protheroe, Valentine Macaulay. University
of Oxford, Oxford, United Kingdom
3594: P-glycoprotein attenuates Src activation and DNA repair activity via increased Cterminal Src kinase-binding protein, a negative regulator of Src, in multidrug-resistant cells
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Li-Fang Lin, Ming-Hsi Wu, Tsann-Long Su, Te-Chang Lee. Academia Sinica - Inst. of
Biomedical Sci., Taipei, Taiwan
3595: In vivo acquired resistance to the mutant EGFR inhibitor Rociletinib (CO-1686) is
associated with activation of the c-MET pathway
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Henry J. Haringsma, Andrew Allen, Thomas C. Harding, Andrew D. Simmons. Clovis
Oncology, Inc., San Francisco, CA
3596: A biomarker study of lapatinib in the neoadjuvant treatment of HER2 over
expressing esophago-gastric adenocarcinoma (EGA)
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Nadeera K. De Silva1, Laura Schulz1, Anna Paterson1, Tara Nuckcheddy-Grant1, Wendi
Qain1, Edmund Godfrey2, Heok Cheow2, Maria O'Donovon2, Minesh Jobanputra3, Daniel
Hochhauser4, Rebecca C. Fitzgerald1, Hugo Ford2. 1University of Cambridge, Cambridge,
United Kingdom; 2Addenbrooke's Hospital, Cambridge, United Kingdom;
3
Galxosmithkline, Stevenage, United Kingdom; 4University College London, London,
United Kingdom
3597: EZH2 D1 domain mutants confer acquired resistance to EZH2-targeted inhibitors
and reprogram B-cell transcription
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Francois Gonzalvez, Theresa Baker, Justin Pritchard, Victor M. Rivera, Andrew Garner.
ARIAD Pharmaceuticals, Inc., Cambridge, MA
3598: Selective internal radiation (SIRT) is most effective when comparing local treatment
to control progressive liver metastases of gastro-intestinal stromal tumors beyond treatment
with tyrosine kinase inhibitors
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Peter Hohenberger1, Nils Rathmann2, Franka Menge1, Maliha Sadick2, Stefan Schönberg2,
Steffen Diehl2. 1Chirurgische Univ. Klinik, Mannheim, Germany; 2Institut für Klinische
Radiologie und Nuklearmedizin, Mannheim, Germany
3599: Resistance mechanisms to HER2-targeting treatment in HER2-positive gastric
cancer
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Kyo Hwa Kang1, Ah-Rong Nam1, Ji Eun Park1, Ju-Hee Bang1, Jin Ling1, Mei Hua Jin1,
Tae Yong Kim2, Sae-Won Han2, Sang-Hyun Song1, Seock-Ah Im2, Tae-You Kim2, DoYoun Oh2, Yung-Jue Bang2. 1Cancer Research Institute, Seoul National University College
of Medicine, Seoul, Korea, Republic of; 2Cancer Research Institute, Seoul National
University College of Medicine, Seoul, Korea; Department of Internal Medicine, Seoul
National University Hospital, Seoul, Korea, Republic of
3600: Impaired taxane binding to MTs in intrinsically taxane resistant gastric cancer cells
without β-tubulin mutation
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Katsuhiro Kita1, Giuseppe Galletti1, Kyle Cleveland1, Prashant V. Thakkar1, Ada Gjyrezi1,
Chao Zhang1, Isabel Barasoain2, J. Fernando Díaz2, Doron Betel1, Manish A. Shah1,
Paraskevi Giannakakou1. 1Weill Medical College of Cornell University, New York, NY;
2
Centro de Investigaciones Biológicas, Consejo Superíor de Investigaciones Científicas
(CIB-CSIC), Madrid, Spain
3601: Antibody-drug conjugates (ADCs) with tubulysin and PBD warheads, maintain
potent in vitro cytotoxicity against multidrug-resistant tumor cells expressing Pglycoprotein (P-gp)
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Shenlan Mao1, Ryan Fleming2, Binyam Bezabeh2, Nazzareno Dimasi2, Dorin Toader2,
Thais Cailleau3, Philip Howard3, Changshou Gao2, Bob Hollingsworth1, Adeela Kamal1,
Jay Harper1. 1Oncology Research, MEDIMMUNE, Gaithersburg, MD; 2Antibody &
Protein Engineering, MEDIMMUNE, Gaithersburg, MD; 3Spirogen, MEDIMMUNE,
Gaithersburg, MD
3602: Cross-resistance to 1st, 2nd, and 3rd generation EGFR tyrosine kinase inhibitors in
vitro is characterized by MET amplification and PTEN loss
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Sarah M. Paul, Dorothee Nickles, Xioafen Ye, Robert L. Yauch, David S. Shames.
Genentech, South San Francisco, CA
3603: Molecular targeting of cetuximab resistant head and neck cancer
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Adam D. Swick, Dana Gunderson, Molly Smith, Grace Blitzer, Andrew Stein, Kwangok P.
Nickel, Randall J. Kimple. University of Wisconsin, Madison, WI
3604: Targeting the PIM kinases in combination with BTK inhibition is synergistic in
preclinical models of B-cell malignancies
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Jeremiah J. Bearss, Brigham L. Bahr, Katie K. Soh, Peter W. Peterson, Clifford J.
Whatcott, Adam Siddiqui-Jain, David J. Bearss, Steven L. Warner. Tolero
Pharmaceuticals, Inc., Lehi, UT
3605: Combined inhibition of IL-1, CXCR1/2, and TGFβ signaling pathways modulates in
vivo acquired resistance to anti-VEGF treatment
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Carmine Carbone, Anna Tamburrino, Geny Piro, Marco Zanotto, Maria Mihaela Mina,
Silvia Zanini, Federico Boschi, Aldo Scarpa, Giampaolo Tortora, Davide Melisi.
University of Verona, Verona, Italy
3606: Increase of MET gene copy number confers resistance to a monovalent MET
antibody and establishes drug dependence.
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Valentina Martin1, Simona Corso2, Paolo Maria Comoglio3, Silvia Giordano4. 1University
of Torino, Department of Oncology; Candiolo Cancer Institute, FPO-IRCCS, Candiolo
(Torino), Italy; 2University of Torino,Department of Oncology; Candiolo Cancer Institute,
FPO-IRCCS;, Candiolo (Torino), Italy; 3University of Torino, Department of Oncology;
Candiolo Cancer Institute, FPO-IRCCS;, Candiolo (Torino), Italy; 4University of Torino,
Department of Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Torino), Italy
3607: Loss-of-function screens using haploid KBM7 and HAP1 cells to identify
mechanisms of anti-cancer drug resistance.
Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Nora M. Gerhards1, Charlotte Guyader2, Vincent A. Blomen2, Aslı Küçükosmanoğlu2, Olaf
van Tellingen2, Daniel J. Vis2, Lodewyk F. Wessels2, Thijn R. Brummelkamp2, Piet Borst2,
Sven Rottenberg1. 1Institute of Animal Pathology, Bern, Switzerland; 2Netherlands Cancer
Institute, Amsterdam, Netherlands
Session Title:
Drug Resistance
Session Type:
Plenary Session
Session Start/End Time: Tuesday, Apr 21, 2015, 8:15 AM -10:15 AM
Location:
Hall A (200 Level), Pennsylvania Convention Center
CME:
CME-Designated
CME/CE Hours:
2
Session Description:
Drug resistance is the primary challenge faced by all practicing
oncologists. The advent of targeted therapies has provided exciting
opportunities not only to understand the mechanisms through which
resistance occurs, but also to design approaches that overcome this
resistance. The presentations in this session will describe the latest
developments in this area of research, from the perspectives of
genetics, drug development, clinical application, and cell biology.
Presentations:
Chairperson
Tuesday, Apr 21, 2015, 8:15 AM -10:15 AM
Bert Vogelstein. Johns Hopkins Kimmel Comp. Cancer Center, Baltimore, MD
Drug resistance: A genetic perspective
Tuesday, Apr 21, 2015, 8:15 AM - 8:45 AM
Bert Vogelstein. Johns Hopkins Kimmel Comp. Cancer Center, Baltimore, MD
Genetic screens to understand drug resistance
Tuesday, Apr 21, 2015, 8:45 AM - 9:15 AM
Alan Ashworth. UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco,
CA
Drug resistance: Translating discoveries into the clinic
Tuesday, Apr 21, 2015, 9:15 AM - 9:45 AM
Alice T. Shaw. Massachusetts General Hospital Cancer Center, Boston, MA
Drug resistance: A cell biologist's perspective
Tuesday, Apr 21, 2015, 9:45 AM -10:15 AM
Joan S. Brugge. Harvard Medical School, Boston, MA
Session Title:
Novel Mechanisms of Drug Response, Sensitivity, or Resistance 1
Session Type:
Poster Session
Session Start/End Time: Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Location:
Section 29
CME:
(not eligible for CME credit)
Session Category:
Experimental and Molecular Therapeutics
Presentations:
4414: RhoA activation in diffuse type gastric adenocarcinoma promotes cancer stem cell
phenotypes including chemotherapy resistance
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Changhwan Yoon, Soo-Jeong Cho, Bulent A. Aksoy, Do Joong Park, Sam S. Yoon.
Memorial Sloan Kettering Cancer Center, New York, NY
4415: Tyrosine phosphorylation is essential for OCT2 function and a target of inhibition by
TKIs
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Navjotsingh Pabla1, Jason A. Sprowl2, Su Sien Ong3, Alice A. Gibson1, Guoqing Du1,
Wenwei Lin3, Shuiying Hu1, Lie Li1, Taosheng Chen3, Alex Sparreboom1. 1Department of
Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN;
2
Department of Pharmaceutical, Social and Administrative Sciences, School of Pharmacy,
D’Youville College, Buffalo, NY; 3Department of Chemical Biology & Therapeutics, St.
Jude Children's Research Hospital, Memphis, TN
4416: Reversal of chemoresistance in ovarian cancer cells by the liposomal co-delivery of
MDR inhibitors and paclitaxel
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Shravan K. Sriraman1, Yilin Zhang2, Ed Luther1, Ernst Lengyel2, Vladimir Torchilin1,
Vladimir Torchilin3. 1Northeastern University, Boston, MA; 2University of Chicago,
Chicago, IL; 3Faculty of Pharmacy, King Abdulaziz University, Saudi Arabia
4417: Vatalanib targets ABCG2-overexpressing multidrug resistant colon cancer cells
under hypoxia
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Kenneth K. To1, Daniel C. Poon1, Yuming Wei1, Fang Wang2, Ge Lin1, Li-wu Fu2. 1The
Chinese University of Hong Kong, Hong Kong, Hong Kong; 2Sun Yat-Sen University,
Guangzhou, China
4418: Autophagy induction contributes to cisplatin resistance in ovarian cancer and is
independent of AKT pathway activity
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Emma L. Kipps1, Mike I. Walton1, Udai Banerji1, Stan B. Kaye2, Michelle D. Garrett3.
1
Institute of Cancer Research, London, United Kingdom; 2The Drug Development Unit,
Royal Marsden NHS Foundation Trust, London, United Kingdom; 3School of Biosciences,
University of Kent, Kent, United Kingdom
4419: Design, synthesis and biological evaluation of N-aryl-3,3,3-trifluoro-2-hydroxy-2methylpropionamide analog as a promising inhibitor of the multidrug resistance-linked
ABCG2 transporter
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Atish S. Patel1, Tianwen Li2, Nagaraju Anreddy3, Yufen Zhao2, Rishil J. Kathawala3, Yijun
Wang3, Suresh V. Ambudkar1, Zhe-Sheng Chen3, Changmei Cheng2. 1National Cancer
Institute, Bethesda, MD; 2Tsinghua University, Bejing, China; 3St. John's University,
Quenns, NY
4420: Factors potentially contributing to sensitivities of CD22-targeting agents in B-cell
malignancies
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Xin Yao, Patricia Burke, Joyce O. Obidi, Xiaoru Chen, Haifeng Bao, Yihong Yao, Jiaqi
Huang. Medimmune LLC, Gaithersburg, MD
4421: GPER-mediated activation of the cAMP response element-binding protein (CREB)
and subsequent IGFBP-1 expression is altered during the development of tamoxifen
resistance
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Ali Vaziri-Gohar1, Kevin D. Houston2. 1New Mexico State University, Molecular Biology
Program, Las Cruces, NM; 2New Mexico State University, Molecular Biology Program
and Chem. Biochem. Department, Las Cruces, NM
4422: TTT-28, a newly synthesized thiazole-valine peptide, antagonizes multidrug
resistance by inhibiting the efflux activity of the ABCB1 transporter
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Yi-Jun Wang1, Nagaraju Anreddy1, Bhargav A. Patel1, Eduardo E. Chufan2, Satyakam
Singh1, Guan-Nan Zhang1, Yun-Kai Zhang1, Anna Maria Barbuti1, Suresh V. Ambudkar1,
Tanaji T. Talele1, Zhe-Sheng Chen1. 1St. John's University, Queens, NY; 2National
Institutes of Health, Bethesda, MD
4423: Chemoresistance regulation by COL11A1 in ovarian cancer
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Yi-Hui Wu. National Cheng Kung University, Tainan, Taiwan
4424: Molecular diagnostics of drug resistant multiple myeloma cases using targeted next
generation sequencing
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Hiroshi Ikeda, Yasushi Sasaki, Tetsuyuki Igarashi, Yuka Aoki, Toshiaki Hayashi, Tadao
Ishida, Takashi Tokino, Yasuhisa Sinomura. Sapporo Medical University, Sapporo, Japan
4425: Multiple -omic analyses of a pair of primary HCC tumor cell lines with different
drug response revealed the mechanisms of drug resistance
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Gang Hu1, Alicia Du1, Yong Huang1, Kunyan Liu1, Fubo Xie1, Xuzhen Tang1, Xueyan
Yang1, Qi Gu1, Yixin Zhang2, Weikang Tao1, Yingjia Zhang1, Wei Tang1, He Zhou1.
1
Shanghai ChemPartner Co., Ltd., Shanghai, China; 2Nantong Cancer Hospital, Nantong,
China
4426: A 13 mer LNA miR-221 inhibitor restores drug sensitivity in melphalan-refractory
multiple myeloma cells
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Annamaria Gulla1, Maria Teresa Di Martino1, Maria Eugenia Gallo Cantafio1, Eugenio
Morelli1, Nicola Amodio1, Cirino Botta1, Maria Rita Pitari1, Santo Giovanni Lio2,
Pierosandro Tagliaferri1, Pierfrancesco Tassone1. 1Magna Graecia University, Catanzaro,
Italy; 2‘‘Giovanni Paolo II’’ Hospital, Lamezia Terme, Italy
4427: Apoptosis, autophagy and ATP: The dynamic interaction of cellular ATP and drug
resistance in MET amplified gastric cancer
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Rebecca Dunbar Schroeder, David Hong, David J. McConkey. UT MD Anderson Cancer
Center, Houston, TX
4428: Metformin effects on ABCB1 expression and proliferation in pancreatic cancer cell
lines with different ABCB1 genotypes/haplotypes
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Beverly D. Lyn-Cook1, Taylor Osborne2, Stancy Joseph1, Beverly Word1, Li Pang1, George
Hammons1. 1FDA-NCTR, Jefferson, AR; 2University of Arkansas at Pine Bluff, Jefferson,
AR
4429: EGR1-MIR152 pathway overcomes acquired cisplatin resistance in ovarian cancer
cells by inhibiting cyto-protective autophagy via ATG14
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Jun He1, Jing-Jie Yu2, Bing-Hua Jiang1. 1Thomas Jefferson University, Philadelphia, PA;
2
West Virginia University, Morgantown, WV
4430: Loss of the histone methyltransferase EZH2 induces chemoresistance in acute
myeloid leukemia (AML)
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Stefanie Göllner1, Shuchi Agrawal-Singh2, Tino Schenk3, Hans-Ulrich Klein4, Christian
Rohde1, Tim Sauer5, Mads Lerdrup2, Sigal Tavor6, Friedrich Stölzel7, Gerhard Ehninger7,
Gabriele Köhler8, Martin Dugas5, Arthur Zelent9, Christian Thiede7, Wolfgang E. Berdel5,
Klaus Hansen2, Carsten Müller-Tidow1. 1University Hospital of Halle (Saale), Halle
(Saale), Germany; 2Biotech Research and Innovation Centre and Centre for Epigenetics,
University of Copenhagen, Copenhagen, Denmark; 3Institute of Cancer Research (ICR),
London, United Kingdom; 4Brigham and Women's Hospital, Harvard Medical School,
Boston, MA; 5University Hospital of Münster, Münster, Germany; 6Goldyne Savad
Institute of Gene Therapy, Jerusalem, Israel; 7University Hospital Carl Gustav Carus,
Dresden, Germany; 8Institute of Pathology, Klinikum Fulda, Fulda, Germany; 9Sylvester
Comprehensive Cancer Center (UMHC), University of Miami, Miami, FL
4431: Musashi enhances GS3K-beta and promotes stemness-related chemoresistance in
glioblastoma
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Hsiao-Yun Chen, Shih-Hwa Chiou. National Yang Ming University, Taipei, Taiwan
4432: A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2mediated MDR in vitro and in vivo
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Nagaraju Anreddy1, Atish Patel1, Yun-Kai Zhang1, Yi-Jun Wang1, Suneet Shukla2, Rishil
J. Kathawala1, Priyank Kumar1, Pranav Gupta1, Suresh V. Ambudkar2, John ND Wurpel1,
Zhe-Sheng Chen1. 1St. John's University, Queens, NY; 2National Institutes of Health,
Bethesda, MD
4433: P-gp-overexpressing MDR cells shed larger extracellular vesicles than their drugsensitive counterparts
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Vanessa Lopes-Rodrigues1, Alessio Di Luca2, Diana Sousa3, Hugo Seca4, Paula Meleady2,
Michael Henry2, Raquel T. Lima5, Robert O'Connor2, M. Helena Vasconcelos3. 1Institute
of Molecular Pathology and Immunology of the University of Porto (IPATIMUP); Institute
of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP); Center of
Medicinal Chemistry of the University of Porto (CEQUIMED-UP), Porto, Portugal;
2
National Institute for Cellular Biotechnology (NICB), Dublin City University, Dublin,
Ireland; 3Institute of Molecular Pathology and Immunology of the University of Porto
(IPATIMUP); Department of Biological Sciences, Laboratory of Microbiology, Faculty of
Pharmacy, University of Porto, Porto, Portugal; 4Institute of Molecular Pathology and
Immunology of the University of Porto (IPATIMUP), Porto, Portugal; 5Institute of
Molecular Pathology and Immunology of the University of Porto (IPATIMUP); Center of
Medicinal Chemistry of the University of Porto (CEQUIMED-UP), Porto, Portugal
4434: Selinexor and melphalan combination therapy for the treatment of multiple myeloma
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Joel G. Turner1, Jana L. Dawson1, Christopher Cubitt1, Taiga Nishihori1, Claudio Anasetti1,
Melissa Alsina1, Rachid C. Baz1, Michael Kauffman2, Sharon Shacham2, William S.
Dalton1, Daniel M. Sullivan1. 1Moffitt Cancer Center & Research Institute, Tampa, FL;
2
Karyopharm Therapeutics, Natick, MA
4436: Metformin upregulates hENT1 expression and enhances gemcitabine efficacy in
pancreatic cancer cells
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Stancy J. Joseph, Taylor Osborne, Beverly Word, Beverly Lyn-Cook. NCTR/FDA,
Jefferson, AR
4437: The relevance of aberrant FPGS splicing for ex vivo MTX resistance and clinical
outcome in childhood acute lymphoblastic leukemia
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Anna Wojtuszkiewicz1, Yehuda G. Assaraf2, Mirthe Hoekstra1, Gerrit Jansen1, Godefridus
J. Peters1, Edwin Sonneveld3, Gertjan L. Kaspers1, Jacqueline Cloos1. 1VU Medical Center,
Amsterdam, Netherlands; 2Technion - Israel Institute of Technology, Haifa, Israel; 3Dutch
Childhood Oncology Group (DCOG), The Hague, Netherlands
4439: Ero1L is a determinant of resistance to bortezomib and collateral sensitivity to MTI101-induced cell death in myeloma
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Michael Emmons1, Lori Hazlehurst1, Steven Escherich1, Mark McLaughlin1, Javier
Cuevas2, Daniel Sullivan1. 1H. Lee Moffitt Cancer Ctr. & Res. Inst., Tampa, FL; 2Univerity
of South Florida, Tampa, FL
4440: The functional role of insulin-like growth factor binding protein-2 in esophageal
adenocarcinoma chemoresistance
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Amy L. Myers, Lin Lin, Derek J. Nancarrow, Zhuwen Wang, Daysha Ferrer-Torres, David
G. Beer, Andrew C. Chang. University of Michigan Medical Center, Ann Arbor, MI
4442: TP53 hot spot mutations in ovarian cancer: Selective resistance to microtubule
stabilizing agents in monoclonal cells and comparison of clinical outcomes from The
Cancer Genome Atlas data
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Brandon-Luke L. Seagle1, Gerda Hofstteter2, Chia-Ping Yang2, Kevin Eng3, Oluwatosin
Odunsi-Akanji1, Kunle Odunsi3, Shohreh Shahabi1. 1Western Connecticut Health Network,
Danbury, CT; 2Albert Einstein College of Medicine, Bronx, NY; 3Roswell Park Cancer
Institute, Buffalo, NY
4443: PB-42: Design and characterization of a glutathione pro-drug selectively delivered to
normal tissue and not tumor tissue
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
James P. Thomas1, Peter G. Geiger2. 1Medical College of Wisconsin, Milwaukee, WI;
2
Persictus Biosciences, Madison, WI
Session Title:
AstraZeneca: Advanced Epidermal Growth Factor Receptor Mutation-
positive Non-small Cell Lung Cancer: Understanding the Drivers of
Resistance
Session Type:
Exhibitor Spotlight Presentation
Session Start/End Time: Tuesday, Apr 21, 2015, 3:00 PM - 4:00 PM
Location:
Exhibitor Spotlight Theater A, Halls B-E
Session Description:
Lung cancer is the second most common cancer among both men and
women in the United States, and despite advances in treatment over the
past several decades, mortality for lung cancer remains high. In a
proportion of non-small cell lung cancer (NSCLC) patients, mutations
in the Epidermal Growth Factor Receptor (EGFR) gene drive tumor
growth and progression, and as a result EGFR has become an important
therapeutic target for these tumors. This presentation aims to educate
on the molecular biology of EGFR mutation-positive (EGFRm)
NSCLC from diagnosis through disease progression and resistance, as
well as educate on patient identification practices at diagnosis and
progression.
Presentation:
Advanced Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung
Cancer: Understanding the Drivers of Resistance
Tuesday, Apr 21, 2015, 3:00 PM - 4:00 PM
Jeffrey Ross, Mark Socinski. AstraZeneca, Pittsburgh, PA
Session Title:
Novel Mechanisms of Drug Response, Sensitivity, or Resistance 2
Session Type:
Poster Session
Session Start/End Time: Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Location:
Section 32
CME:
(not eligible for CME credit)
Session Category:
Experimental and Molecular Therapeutics
Presentations:
5449: Transfection of connexin 43 enhances sunitinib-induced apoptosis in malignant
mesothelioma cells possibly via its interaction with Bax
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Miaki Uzu, Hiromi Sato, Tatsuro Kashiba, Takuya Fujiwara, Yukihiro Shibata, Katsunori
Yamaura, Akihiro Hisaka. Chiba University, Chiba, Japan
5450: Naturally occurring mutations in the MPS1 gene predispose cells to kinase
inhibitor drug-resistance
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Mark D. Gurden, Isaac Westwood, Amir Faisal, Sébastien Naud, Jack Cheung, Craig
McAndrew, Amy Wood, Jessica Schmitt, Kathy Boxall, Grace Mak, Paul Workman,
Rosemary Burke, Swen Hoelder, Julian Blagg, Rob Van Montfort, Spiros Linardopoulos.
Institute of Cancer Research, London, United Kingdom
5451: Over-expression of NPM-ALK drives resistance to TKIs in ALK+ ALCL but is
toxic upon drug withdrawal, permitting prolonged tumour control through discontinuous
dosing
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Soumya Sundara Rajan, Amit Dipak Amin, Matthew Groysman, Praechompoo
Pongtornpipat, Jonathan Schatz. University Of Arizona, Tucson, AZ
5452: Inhibition of sodium-independent and sodium-dependent nucleobase transport
activities by tyrosine kinase inhibitors
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Vijaya L. Damaraju, Michelle Kuzma, Carol E. Cass, Michael B. Sawyer. Cross Cancer
Inst., Edmonton, AB, Canada
5453: Different mechanism of Oxaliplatin resistance in human colorectal cancer cell lines
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Tomoki Yamano, Shuji Kubo, Aya Yano, Naohiro Tomita. Hyogo College of Medicine,
Nishinomiya, Japan
5454: Wogonin overcomes cisplatin resistance of head and neck cancer by targeting
antioxidant defense mechanisms
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Ji Won Kim, Eun Hye Kim, Jin Young Park, Minsu Kwon, Jong-Lyel Roh. Asan
Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
5455: Surface accumulation of receptor tyrosine kinases upon treatment with tyrosine
kinase inhibitors and resulting enhancement of activity upon treatment cessation
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Anne-Mette Bjerregaard, Michael V. Grandal, Camilla Frohlich, Trine Lindsted,
Christina Egebjerg, Ivan D. Horac, Michael Kragh, Mikkel W. Pedersen. Symphogen
A/S, Ballerup, Denmark
5456: FGF9 gene amplification can induce resistance to anti-EGFR therapy in colorectal
cancer
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Takuro Mizukami1, Yosuke Togashi2, Eri Banno2, Masato Terashima2, Marco A de
velasco2, Kazuko Sakai2, Yoshihiko Fujita2, Shuta Tomida2, Takako Eguchi Nakajima1,
Narikazu Boku1, Kazuto Nishio2. 1St.Marianna university school of medicine, Kanagawa,
Japan; 2Kinki university faculty of medicine, Osaka, Japan
5457: MAD2γ, a new MAD2 isoform, is ubiquitously expressed in distinct cell lines,
reduces mitotic arrest, and associates with resistance to cisplatin-based chemotherapy in
testicular germ cell tumors
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Alejandro Lopez-Saavedra, Rodrigo Caceres, Fernando Luna, Irwin Hernandez, Luis
Alonso Herrera. Inst. Nacional de Cancerología, Mexico, Mexico
5458: Elevated level of Fibrillarin induces chemoresistance by interfering p53 pathway in
cancers
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Teng Xu1, Suthakar Ganapathy2, Meijun Long3, Chul Ha1, Zhi-Min Yuan2, Hang Su1.
1
University of Texas Health Science Center at SA, san anotnio, TX; 2Harvard School of
Public Health, Boston, MA; 3The Third Affiliated Hospital of Sun Yat-sen University,
Guangzhou, China
5459: Overcoming resistance to HER2-targeting drugs using CDK8 inhibitors
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Martina McDermott1, Laura Ivers2, Norma O'Donovan2, John Crown3, Igor Roninson1,
Eugenia V. Broude1. 1University of South Carolina College of Pharmacy, Columbia, SC;
2
National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland;
3
St. Vincent's University Hospital, Dublin, Ireland
5460: Prevention of peritonitis carcinomatosa after adjuvant chemotherapy by the
inhibition of RNA polymerase in drug-tolerant subpopulations
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Satoshi S. Nishizuka, Kohei Kume, Kei Sato, Takeshi Iwaya, Go Wakabayashi. Iwate
Medical University School of Medicine, Morioka, Japan
5461: Triapine-mediated ABCB1 induction via PKC induces widespread therapy
unresponsiveness but is not underlying acquired triapine resistance
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Walter Miklos1, Karla Pelivan2, Christian Kowol2, Rita Dornetshuber-Fleiss2, Melanie
Spitzwieser2, Margit Cichna-Markl2, Gunda Köllensperger2, Bernhard Keppler2, Walter
Berger1, Petra Heffeter1. 1Medical University of Vienna, Vienna, Austria; 2University of
Vienna, Vienna, Austria
5462: Extracellular ATP promotes cancer cell drug resistance to tyrosine kinase
inhibitors by competing for the ATP-binding site of tyrosine kinase
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Xuan Wang, Yanrong Qian, Yunsheng Li, Xiaozhuo Chen. Ohio University, Athens, OH
5463: Role of the endothelin axis in astrocyte and endothelial cell mediated
chemoprotection of cancer cells
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Mark S. Kim, Hyun Jin Choi, Ho-Jeong Lee, Junqin He, Qiuyu We, Robert R. Langley,
Sin-Jin Kim, Isaiah J. Fidler. UT MD Anderson Cancer Center, Houston, TX
5464: Host variation in OATP1B1 is associated with treatment outcome in pediatric
AML
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Christina D. Drenberg, Stanley Pounds, Lei Shi, Shelley Orwick, Lie Li, Shuiying Hu,
Alice Gibson, Raul Ribeiro, Jeffrey Rubnitz, Alex Sparreboom, Sharyn D. Baker. St.
Jude Children's Research Hospital, Memphis, TN
5465: Systematic interrogation of druggable pathways in pancreatic adenocarcinomas
using pooled gene-knockdown lentiviral libraries
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Edgar Ferrer-Lorenzo, Daniel P. Nussbaum, Peter Winter, Kris Wood. Duke University,
Durham, NC
5466: Integrative TCGA analyses identify Basonuclin1 (BNC1) as a key mediator for
platinum resistance
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Sherry Y. Wu, Justyna Filant, Michael McGuire, Rajesha Rupaimoole, Sunila Pradeep,
Anna Unruh, Herbrich Shelley, Cristina Ivan, Ruder Dennis, Cristian Rodriguez-Aguayo,
Vasudha Sehgal, Takahito Miyake, Archana Nagaraja, Kshipra Gharpure, Guillermo
Armaiz, Rebecca Previs, Gabriel Lopez-Berestein, Prahlad Ram, Keith Baggerly, Anil
Sood. University of Texas M.D. Anderson Cancer Center, Houston, TX
5467: BRCA1 N-terminal-deficient proteins provide PARP inhibitor and platinum
resistance
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Yifan Wang1, Andrea Bernhardy1, Emmanuelle Nicolas1, Ryan Winters1, Kathy Cai1,
Kelly Duncan1, James Duncan1, Maria Harrell2, Elizabeth Swisher2, Neil Johnson1. 1Fox
Chase Cancer Center, Philadelphia, PA; 2University of Washington, Seattle, WA
5468: Tirapazamine as a strategy to prevent cell dissemination and overcome drug
resistance
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Barbara Muz, Pilar de la Puente, Feda Azab, Micah Luderer, Abdel Kareem Azab.
Washington University in St Louis, Saint Louis, MO
5469: Dexamethasone interrupts paclitaxel-induced apoptosis in solid tumor cells
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Marianna Zavodovskaya, Carrie Brachmann, Jorge DiMartino, Daniel Pierce. Celgene,
San Francisco, CA
5470: Blocking wound-induced tumor repopulation between chemotherapy cycles as a
novel approach to abrogate chemoresistance
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Antonina V. Kurtova, Jing Xiao, Qianxing Mo, Senthil Pazhanisamy, Ross Krasnow,
Seth P. Lerner, Fengju Chen, Terrence Roh, Erica Lay, Philip L. Ho, Keith S. Chan.
Baylor College of Medicine, Houston, TX
5471: Identification of OAT1/OAT3 as contributors to cisplatin nephrotoxicity
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Shuiying Hu1, Navjotsingh Pabla1, Laura J. Janke1, Lie Li1, Aksana Vasilyeva1, Jason A.
Sprowl2, Alex Sparreboom1. 1St. Jude Children's Research Hospital, Memphis, TN;
2
D'Youville College, Buffalo, NY
5472: Selinexor, a selective inhibitor of nuclear export (SINE), acts through NF-κB
deactivation and combines with proteasome inhibitors to synergistically induce tumor
cell death
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Yosef Landesman, Trinayan Kashyap, Marsha Crochiere, Boris Klebanov, Sharon
Friedlander, William Senapedis, Robert Carlson, Michael Kauffman, Sharon Shacham.
Karyopharm Therapeutics, Newton, MA
5473: Human cancer cells acquire chemoresistance to gemcitabine mainly through lossof-function mutations in the DCK gene
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Akira Horii, Yuriko Saiki, Tomohiro Nakano, Chiharu Kudo, Makoto Sunamura. Tohoku
Univ. School of Medicine, Sendai, Japan
5474: PD-L1 regulates cisplatin chemoresistance in head and neck squamous cell
carcinoma
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Randall S. Ruffner, Andrew Ramsey, Bert W. O'Malley, Jr., Daqing Li. University of
Pennsylvania, Philadelphia, PA
5475: Cancer exosome promotes cisplatin resistance In bladder cancer and inhibition of
exosome sensitizes bladder cancer cells to cisplatin chemotherapy
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Chiahao Wu1, Chris Silvers1, Elizabeths Guancial1, Jong-Wei Hsu2, Edward Messing1,
Yi-Fen Lee1. 1University of Rochester, Rochester, NY; 2Cornell University, Ithaca, NY
5476: A novel PARP inhibitor resistance mechanism mediated by the RNA-binding
protein HuR
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Saswati N. Chand1, Akshay R. Kamath1, Nicole Meisner-Kober2, Charles J. Yeo1, Jordan
M. Winter1, Jonathan R. Brody1. 1Thomas Jefferson University, Philadelphia, PA;
2
Novartis Institutes for Biomedical Research, Basel, Switzerland
5477: MERIT40 is an Akt substrate that promotes resolution of DNA damage induced by
chemotherapy
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Kristin K. Brown, Laleh Montaser-Kouhsari, Andrew H. Beck, Alex Toker. Beth Israel
Deaconess Medical Center, Boston, MA
5478: Curcumin mediates reversion to oxaliplatin-acquired resistance in colorectal cancer
cell lines through modulation of nuclear factor κB (NFκB) and cyclin-dependent kinase 5
(CDK5)
Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
Vicenç Ruiz de Porras1, Sara Bystrup1, Anna Martinez-Cardus2, Alba Ginés1, Laura
Layos3, José Luis Manzano3, Cristina Bugés3, Albert Abad4, Eva Martinez-Balibrea1.
1
Institut d'investigació en ciències de la salut Germans Trias i Pujol (IGTP), Badalona,
Spain; 2Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research
Institute, L'Hospitalet de LLobregat, Spain; 3Catalan Institut of Oncology, Badalona,
Spain; 4Oncology Unit, Hospital CIMA Sanitas, Barcelona, Spain